Reported 8 months ago
In Taipei on June 20, 2024, at 4:10 PM, YingShuo transferred the products primarily focused on central nervous system medications, including two market licenses for oral medications to treat epilepsy and oral liquid drugs, to JianQiao. This alliance not only enriches JianQiao's product line and expands its market penetration but also allows YingShuo to receive signing and milestone fees. The products transferred include central nervous system medications for treating epilepsy and oral liquid drugs, along with the development technology of a new generation of antiepileptic drugs, offering higher safety compared to traditional options. YingShuo and JianQiao deepened their collaboration, aiming to create a win-win situation and further boost the pharmaceutical industry in Taiwan.
Source: YAHOO